Provided by Tiger Trade Technology Pte. Ltd.

Cerenome, Inc

0.7561
-0.1941-20.43%
Volume:765.38K
Turnover:616.40K
Market Cap:5.74M
PE:-0.17
High:0.9875
Open:0.9682
Low:0.6821
Close:0.9502
52wk High:18.89
52wk Low:0.4287
Shares:7.59M
Float Shares:6.46M
Volume Ratio:0.72
T/O Rate:11.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3700
EPS(LYR):-7.2500
ROE:-1468.02%
ROA:-118.94%
PB:-6.22
PE(LYR):-0.10

Loading ...

Cerenome, Inc Reports Results for the Quarter Ended September 30 - Earnings Summary

Reuters
·
Yesterday

Cerenome Reports no Dose-Limiting Toxicities in Interim Reyobiq Repeat-Dose Study

Reuters
·
Yesterday

Cerenome - no Dose-Limiting Toxicities or Adverse Events Leading to Discontinuation Reported

THOMSON REUTERS
·
Yesterday

Cerenome Reports Interim Respect-Lm Data Supporting Repeat Dosing of Reyobiq™ in Leptomeningeal Metastases at the 2026 Sno Annual Meeting

THOMSON REUTERS
·
Yesterday

Cerenome Faces Funding Uncertainty as Conditions Threaten Access to Remaining Convertible Note Capital

TIPRANKS
·
Nov 15

Cerenome Q3 EPS $(1.14) Misses $(0.95) Estimate, Sales $722.000K Miss $920.333K Estimate

Benzinga Earnings
·
Nov 14

Press Release: Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring Reyobiq ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress

Dow Jones
·
Nov 14

Cerenome, Inc Expected to Post a Loss of 96 Cents a Share - Earnings Preview

Reuters
·
Nov 13

Cerenome Updates Financial Calendar

Reuters
·
Nov 12

Cerenome to Review Reyobiq Respect-Lm Data Presented at Sno Conference and Provide Cnside Commercial Update on November 16

THOMSON REUTERS
·
Nov 12

Cerenome Appoints Director Ron Andrews as Chief Business Officer

Reuters
·
Nov 12

Cerenome Appoints Director Ron Andrews as Chief Business Officer

THOMSON REUTERS
·
Nov 10

Press Release: Cerenome Appoints Director Ron Andrews as Chief Business Officer

Dow Jones
·
Nov 10

Cerenome Secures National In-Network Agreement with Aetna for CNSide Tests

Reuters
·
Nov 04

Cerenome - Agreement Establishes Reimbursement for Cnside Csf Tumor Cell Enumeration and Molecular Profile Tests

THOMSON REUTERS
·
Nov 04

Cerenome Secures National In-Network Agreement with Aetna for Cnside®

THOMSON REUTERS
·
Nov 04

NASDAQ Trade Halt Volatility Trading Pause at 10:24 Am

Reuters
·
Nov 03

Cerenome Completes Enrollment in Phase 2 Reyobiq Trial for Recurrent Glioblastoma

Reuters
·
Oct 29

Cerenome Completes Enrollment in Phase 2 Respect-GBM Trial of Reyobiq™ in Recurrent Glioblastoma

THOMSON REUTERS
·
Oct 29

Cerenome - Expects Topline Phase 2 Respect-GBM Data in Mid-2027

THOMSON REUTERS
·
Oct 29